RBC Capital analyst Brian Abrahams maintained a Buy rating on Ovid Therapeutics (OVID) on August 10 and set a price target of $13.00. The company’s shares closed last Tuesday at $7.02.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 10.7% and a 51.0% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ovid Therapeutics with a $13.60 average price target, implying a 91.5% upside from current levels. In a report issued on August 3, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Ovid Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $20.03 million. In comparison, last year the company had a GAAP net loss of $13.8 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
